Molecular epidemiology of antibiotic-resistant Gram-negative bacilli in a neonatal intensive care unit during a nonoutbreak period.
van den Anker
John N
JN
D000658:Amoxicillin / Q000627:therapeutic use; D002439:Cefotaxime / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial / Q000502:physiology*; D004359:Drug Therapy, Combination; D004754:Enterobacter / Q000187:drug effects / Q000254:growth & development; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000453:epidemiology; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007231:Infant, Newborn; D007363:Intensive Care Units, Neonatal / Q000592:standards / Q000706:statistics & numerical data*; D007902:Length of Stay; D017720:Molecular Epidemiology; D010406:Penicillins / Q000627:therapeutic use; D012307:Risk Factors; D014031:Tobramycin / Q000627:therapeutic use
D010406:Penicillins; D000658:Amoxicillin; D002439:Cefotaxime; D014031:Tobramycin